Where is IRONWOOD PHARMACEUTICALS headquartered?

IRONWOOD PHARMACEUTICALS INC is recorded with headquarters in Boston, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is IRONWOOD PHARMACEUTICALS publicly traded?

Yes — IRONWOOD PHARMACEUTICALS is listed as a public company with ticker IRWD on NYSE in SEC EDGAR-derived records.

What drugs are associated with IRONWOOD PHARMACEUTICALS?

We link 1 drug profile(s) where IRONWOOD PHARMACEUTICALS appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is IRONWOOD PHARMACEUTICALS sponsoring?

IRONWOOD PHARMACEUTICALS is linked to 33 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list IRONWOOD PHARMACEUTICALS as applicant?

45 USPTO PatentsView record(s) name IRONWOOD PHARMACEUTICALS INC or a normalized variant as applicant.

What pipeline phases does IRONWOOD PHARMACEUTICALS have in our database?

Phase distribution from linked programs: phase 2: 15, phase 3: 11, approved: 3, phase 1: 2.

How many US-approved drugs are linked to IRONWOOD PHARMACEUTICALS?

1 linked drug profile(s) include US approval status in openFDA-derived metadata.

Does IRONWOOD PHARMACEUTICALS hold EU marketing authorisations in our data?

1 linked drug(s) include EMA EPAR approval metadata.

Where does NovaPharmaNews source data on IRONWOOD PHARMACEUTICALS?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is IRONWOOD PHARMACEUTICALS data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

pharma · Irritable Bowel Syndrome With Constipation · Chronic Constipation · IRWD

IRONWOOD PHARMACEUTICALS

Name: IRONWOOD PHARMACEUTICALS intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

IRONWOOD PHARMACEUTICALS INC

Website Investor relations

100 Summer Street, Boston, MA 02110, US HQ

1998 Founded

262 Employees

Public company Type

IRWD · NYSE Ticker

Company details

Status: Public
HQ: 100 Summer Street, Boston, MA 02110, US
Founded: 1998
Employees: 262
Programs: 33
Drugs: 11
Patents: 45

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

IRONWOOD PHARMACEUTICALS is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker IRWD. Primary therapeutic focus areas include Irritable Bowel Syndrome With Constipation, Chronic Constipation, Constipation, Irritable Bowel Syndrome Characterized by Constipation, Interstitial Cystitis. NovaPharmaNews links 33 clinical program(s), 1 drug profile(s), and 45 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (15), phase 3 (11), approved (3).

Company snapshot

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of [Gerald Fink](en.wikipedia.org/wiki/Gerald_Fink) at the [Whitehead Institute](en.wikipedia.org/wiki/Whitehead_Institut) to commercialize approaches that had been developed in the lab to improve [industrial fermentation](en.wikipedia.or

2 approved product(s) across US/EU regulatory metadata.
33 active pipeline program(s) linked via ClinicalTrials.gov.
45 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for IRONWOOD PHARMACEUTICALS. Not investment advice.

Top assets

View drugs (11) View projects (33)

Lead pipeline drugs

colchicine
approved
ethinyl estradiol
approved
ispaghula husk product
Marketed / approved
lesinurad
approved

Active clinical programs

IW-3718 Gastroesophageal Reflux Disease (GERD)
Phase 3
LIN-MD-66 Irritable Bowel Syndrome With Constipation
Phase 3
Linaclotide Chronic Idiopathic Constipation
Phase 3
Linaclotide Functional Constipation
Phase 3

Momentum

Proprietary activity score for IRONWOOD PHARMACEUTICALS.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 41 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Phathom Pharmaceuticals

TA overlap score 22.2

Recent activity

Latest pipeline, patent, and corporate events for IRONWOOD PHARMACEUTICALS.

Jun 8, 2026 Clinical update
LIN-MD-66 — Phase 3
Jun 8, 2026 Clinical update
Placebo for Linaclotide — Phase 3
Jun 8, 2026 Clinical update
Linaclotide or Matching Placebo — Phase 3
Jun 8, 2026 Clinical update
Linaclotide Dose A — Phase 2
Jun 8, 2026 Clinical update
Linaclotide Acetate — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is IRONWOOD PHARMACEUTICALS?

IRONWOOD PHARMACEUTICALS is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker IRWD. Primary therapeutic focus areas include Irritable Bowel Syndrome With Constipation, Chronic Constipation, Constipation, Irritable Bowel Syndrome Characterized by C
Is IRONWOOD PHARMACEUTICALS publicly traded?

Yes. IRONWOOD PHARMACEUTICALS is listed with ticker IRWD on NYSE per SEC EDGAR records linked on this profile.
What drugs does IRONWOOD PHARMACEUTICALS develop or market?

We link 11 drug profile(s) where IRONWOOD PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc#company-drugs.
What are the latest developments for IRONWOOD PHARMACEUTICALS?

In the last 12 months our linked public records show 33 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does IRONWOOD PHARMACEUTICALS focus on?

IRONWOOD PHARMACEUTICALS focuses on Irritable Bowel Syndrome With Constipation, Chronic Constipation, Constipation based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Cardiology